<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated">
      <PMID Version="1">32059832</PMID>
      <DateCompleted>
        <Year>2020</Year>
        <Month>10</Month>
        <Day>23</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2020</Year>
        <Month>10</Month>
        <Day>23</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1878-1594</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>34</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2020</Year>
              <Month>Jan</Month>
            </PubDate>
          </JournalIssue>
          <Title>Best practice &amp; research. Clinical endocrinology &amp; metabolism</Title>
          <ISOAbbreviation>Best Pract Res Clin Endocrinol Metab</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Graves' disease: Clinical manifestations, immune pathogenesis (cytokines and chemokines) and therapy.</ArticleTitle>
        <Pagination>
          <StartPage>101388</StartPage>
          <MedlinePgn>101388</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.beem.2020.101388</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S1521-690X(20)30015-4</ELocationID>
        <Abstract>
          <AbstractText>Graves' disease (GD) is characterized by thyrotoxicosis, caused by the presence of circulating thyroid stimulating antibodies (TSAb), that are determinant also in the pathogenesis of its extrathyroidal manifestations [Graves' ophthalmopathy (GO), pretibial myxedema]. T helper (Th)1 immune response prevails in the immune-pathogenesis of GD and GO, during the active phase, when Th1 chemokines, and their (C-X-C)R3 receptor, play a key role. In GD, the existing treatments are not ideal for hyperthyroidism (long-term remission with anti-thyroid-drugs only in 50% of patients; while radioiodine and surgery cause hypothyroidism). In GD, antigen-specific therapy has been recently published, with the induction of T cell tolerance via an immunization by TSH-R peptides. In GO, rituximab and drugs targeting cytokines have been evaluated. Furthermore, teprotumumab (a human monoclonal anti-IGF-1R blocking antibody) showed to be very effective in GO patients. Further researches are necessary to identify novel effective therapies targeting GD, or GO.</AbstractText>
          <CopyrightInformation>Copyright Â© 2020 Elsevier Ltd. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Antonelli</LastName>
            <ForeName>Alessandro</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy. Electronic address: alessandro.antonelli@med.unipi.it.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Fallahi</LastName>
            <ForeName>Poupak</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Translational Research and of New Technologies in Medicine and Surgery, University of Pisa, 56126, Pisa, Italy. Electronic address: poupak.fallahi@unipi.it.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Elia</LastName>
            <ForeName>Giusy</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy. Electronic address: e.giusy_87@hotmail.it.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ragusa</LastName>
            <ForeName>Francesca</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy. Electronic address: francescaragusa86@gmail.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Paparo</LastName>
            <ForeName>Sabrina Rosaria</ForeName>
            <Initials>SR</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy. Electronic address: sabrinapaparo@gmail.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ruffilli</LastName>
            <ForeName>Ilaria</ForeName>
            <Initials>I</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy. Electronic address: ilaria.ruffilli@gmail.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Patrizio</LastName>
            <ForeName>Armando</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy. Electronic address: armandopatrizio125@gmail.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gonnella</LastName>
            <ForeName>Debora</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy. Electronic address: debora.gonnella@icloud.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Giusti</LastName>
            <ForeName>Claudia</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy. Electronic address: claudiagiusti94@gmail.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Virili</LastName>
            <ForeName>Camilla</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Sapienza University of Rome, 9311, Medicosurgical Sciences and Biotechnologies, C.so della Repubblica 79, Latina, 04100, Italy. Electronic address: camilla.virili@uniroma1.it.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Centanni</LastName>
            <ForeName>Marco</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Sapienza University of Rome, 9311, Medicosurgical Sciences and Biotechnologies, C.so della Repubblica 79, Latina, 04100, Italy; ASL Latina, 217138, Endocrinology Unit, Latina, Lazio, Italy. Electronic address: marco.centanni@uniroma1.it.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Shoenfeld</LastName>
            <ForeName>Yehuda</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Tel-Hashomer, Israel; Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel; I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University), Russia. Electronic address: Yehuda.Shoenfeld@sheba.health.gov.il.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ferrari</LastName>
            <ForeName>Silvia Martina</ForeName>
            <Initials>SM</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy. Electronic address: sm.ferrari@int.med.unipi.it.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2020</Year>
          <Month>02</Month>
          <Day>04</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Netherlands</Country>
        <MedlineTA>Best Pract Res Clin Endocrinol Metab</MedlineTA>
        <NlmUniqueID>101120682</NlmUniqueID>
        <ISSNLinking>1521-690X</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D018925">Chemokines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D016207">Cytokines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D007457">Iodine Radioisotopes</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D015551" MajorTopicYN="N">Autoimmunity</DescriptorName>
          <QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018925" MajorTopicYN="N">Chemokines</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006111" MajorTopicYN="Y">Graves Disease</DescriptorName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D049970" MajorTopicYN="N">Graves Ophthalmopathy</DescriptorName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
          <QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007457" MajorTopicYN="N">Iodine Radioisotopes</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">CXCL10</Keyword>
        <Keyword MajorTopicYN="Y">CXCR3</Keyword>
        <Keyword MajorTopicYN="Y">Graves' disease</Keyword>
        <Keyword MajorTopicYN="Y">Graves' ophthalmopathy</Keyword>
        <Keyword MajorTopicYN="Y">Th1 immune response</Keyword>
        <Keyword MajorTopicYN="Y">teprotumumab</Keyword>
      </KeywordList>
      <CoiStatement>Declaration of Competing Interest The Authors have nothing to declare.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2020</Year>
          <Month>2</Month>
          <Day>16</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2020</Year>
          <Month>10</Month>
          <Day>24</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2020</Year>
          <Month>2</Month>
          <Day>16</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">32059832</ArticleId>
        <ArticleId IdType="doi">10.1016/j.beem.2020.101388</ArticleId>
        <ArticleId IdType="pii">S1521-690X(20)30015-4</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
